EA201071340A1 - Материалы и способы для подавления и/или лечения нейрофибромы и пограничных опухолей - Google Patents
Материалы и способы для подавления и/или лечения нейрофибромы и пограничных опухолейInfo
- Publication number
- EA201071340A1 EA201071340A1 EA201071340A EA201071340A EA201071340A1 EA 201071340 A1 EA201071340 A1 EA 201071340A1 EA 201071340 A EA201071340 A EA 201071340A EA 201071340 A EA201071340 A EA 201071340A EA 201071340 A1 EA201071340 A1 EA 201071340A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tumor
- cells
- neurofibroma
- hematopoietic cells
- plexiform
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Генеративные мутации в гене-супрессоре опухолевого роста NF1 являются причиной нейрофиброматоза фон Реклингхаузена типа 1 (NF1), общеизвестного генетического заболевания нервной системы, характеризующегося развитием плексиформных нейрофибром. Используя адоптивный перенос гемопоэтических клеток, авторы установили, что NF1 гетерозиготность происходящих из костного мозга клеток в опухолевом микроокружении является достаточным фактором для того, чтобы вызвать образование опухоли, при условии нуль-зиготности Шванновских клеток. Кроме того, генетическое или фармакологическое ослабление c-Kit сигнального пути в гемопоэтических клетках значительно уменьшает возникновение и развитие нейрофибромы. Эти исследования показали, что гаплонедостаточные гемопоэтические клетки и c-Kit рецептор являются терапевтическими мишенями для предотвращения образования плексиформных нейрофибром, а также позволили прийти к заключению, что мастоциты являются ключевыми медиаторами при возникновении опухоли. Введение терапевтически эффективных доз ингибитора тирозинкиназы, такого как химическое соединение иматиниба мезилат, нуждающемуся в этом пациенту излечивает опухоли у человека, пораженного плексиформной нейрофибромой.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7618508P | 2008-06-27 | 2008-06-27 | |
| US10365008P | 2008-10-08 | 2008-10-08 | |
| PCT/US2009/048554 WO2009158447A2 (en) | 2008-06-27 | 2009-06-25 | Materials and methods for suppressing and/or treating neurofibroma and related tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201071340A1 true EA201071340A1 (ru) | 2011-12-30 |
| EA022611B1 EA022611B1 (ru) | 2016-02-29 |
Family
ID=41445287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201500525A EA201500525A1 (ru) | 2008-06-27 | 2009-06-25 | Материалы и способы для подавления и/или лечения нейрофибромы и пограничных опухолей |
| EA201071340A EA022611B1 (ru) | 2008-06-27 | 2009-06-25 | Способ лечения плексиформной нейрофибромы |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201500525A EA201500525A1 (ru) | 2008-06-27 | 2009-06-25 | Материалы и способы для подавления и/или лечения нейрофибромы и пограничных опухолей |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20110195975A1 (ru) |
| EP (1) | EP2291186A4 (ru) |
| JP (2) | JP2011526292A (ru) |
| KR (2) | KR20160011713A (ru) |
| CN (2) | CN102099038A (ru) |
| AU (1) | AU2009262214B9 (ru) |
| BR (1) | BRPI0914618A2 (ru) |
| CA (1) | CA2727737C (ru) |
| CL (1) | CL2009001486A1 (ru) |
| EA (2) | EA201500525A1 (ru) |
| IL (1) | IL209973A (ru) |
| MA (1) | MA32419B1 (ru) |
| MX (1) | MX2010013918A (ru) |
| NZ (1) | NZ590076A (ru) |
| SG (1) | SG192444A1 (ru) |
| TW (1) | TWI508728B (ru) |
| WO (1) | WO2009158447A2 (ru) |
| ZA (1) | ZA201009066B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3381943T3 (da) | 2012-07-25 | 2022-05-16 | Celldex Therapeutics Inc | Anti-kit-antistoffer og anvendelser deraf |
| JP6768639B2 (ja) * | 2014-05-23 | 2020-10-21 | セルデックス セラピューティクス，インコーポレーテッド | 好酸球又はマスト細胞関連障害の治療 |
| KR101894769B1 (ko) | 2017-12-05 | 2018-09-04 | 아주대학교산학협력단 | siRNA를 포함하는 신경섬유육종 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| CA2439440A1 (en) * | 2002-09-05 | 2004-03-05 | Emory University | Treatment of tuberous sclerosis associated neoplasms |
| CA2629132C (en) * | 2005-12-06 | 2014-05-27 | Novartis Ag | Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis |
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
-
2009
- 2009-06-25 KR KR1020167001722A patent/KR20160011713A/ko not_active Application Discontinuation
- 2009-06-25 NZ NZ590076A patent/NZ590076A/xx not_active IP Right Cessation
- 2009-06-25 CA CA2727737A patent/CA2727737C/en not_active Expired - Fee Related
- 2009-06-25 EA EA201500525A patent/EA201500525A1/ru unknown
- 2009-06-25 BR BRPI0914618A patent/BRPI0914618A2/pt not_active IP Right Cessation
- 2009-06-25 SG SG2013049952A patent/SG192444A1/en unknown
- 2009-06-25 EP EP09770980A patent/EP2291186A4/en not_active Withdrawn
- 2009-06-25 JP JP2011516634A patent/JP2011526292A/ja active Pending
- 2009-06-25 CN CN2009801234742A patent/CN102099038A/zh active Pending
- 2009-06-25 US US12/996,891 patent/US20110195975A1/en not_active Abandoned
- 2009-06-25 KR KR1020107028646A patent/KR20110044945A/ko active Search and Examination
- 2009-06-25 AU AU2009262214A patent/AU2009262214B9/en not_active Ceased
- 2009-06-25 EA EA201071340A patent/EA022611B1/ru not_active IP Right Cessation
- 2009-06-25 CL CL2009001486A patent/CL2009001486A1/es unknown
- 2009-06-25 WO PCT/US2009/048554 patent/WO2009158447A2/en active Application Filing
- 2009-06-25 TW TW098121297A patent/TWI508728B/zh not_active IP Right Cessation
- 2009-06-25 MX MX2010013918A patent/MX2010013918A/es active IP Right Grant
- 2009-06-25 CN CN201610089818.4A patent/CN105726542A/zh active Pending
-
2010
- 2010-12-13 IL IL209973A patent/IL209973A/en not_active IP Right Cessation
- 2010-12-17 ZA ZA2010/09066A patent/ZA201009066B/en unknown
- 2010-12-27 MA MA33461A patent/MA32419B1/fr unknown
-
2013
- 2013-09-20 US US14/032,994 patent/US8933082B2/en not_active Expired - Fee Related
-
2014
- 2014-11-18 US US14/546,827 patent/US9345704B2/en not_active Expired - Fee Related
-
2015
- 2015-04-01 JP JP2015075280A patent/JP2015187104A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110044945A (ko) | 2011-05-03 |
| IL209973A (en) | 2015-11-30 |
| AU2009262214A1 (en) | 2009-12-30 |
| TWI508728B (zh) | 2015-11-21 |
| EA201500525A1 (ru) | 2015-11-30 |
| JP2015187104A (ja) | 2015-10-29 |
| MA32419B1 (fr) | 2011-06-01 |
| JP2011526292A (ja) | 2011-10-06 |
| WO2009158447A2 (en) | 2009-12-30 |
| US9345704B2 (en) | 2016-05-24 |
| SG192444A1 (en) | 2013-08-30 |
| US20150072992A1 (en) | 2015-03-12 |
| NZ590076A (en) | 2012-11-30 |
| US20140121214A1 (en) | 2014-05-01 |
| US20110195975A1 (en) | 2011-08-11 |
| CL2009001486A1 (es) | 2010-04-16 |
| IL209973A0 (en) | 2011-02-28 |
| EA022611B1 (ru) | 2016-02-29 |
| AU2009262214B2 (en) | 2014-12-11 |
| EP2291186A4 (en) | 2011-06-22 |
| KR20160011713A (ko) | 2016-02-01 |
| CN105726542A (zh) | 2016-07-06 |
| CA2727737A1 (en) | 2009-12-30 |
| ZA201009066B (en) | 2011-08-31 |
| TW201006472A (en) | 2010-02-16 |
| CA2727737C (en) | 2016-08-23 |
| EP2291186A2 (en) | 2011-03-09 |
| AU2009262214B9 (en) | 2015-04-30 |
| US8933082B2 (en) | 2015-01-13 |
| CN102099038A (zh) | 2011-06-15 |
| BRPI0914618A2 (pt) | 2017-06-06 |
| WO2009158447A9 (en) | 2010-03-25 |
| MX2010013918A (es) | 2011-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
| NZ592425A (en) | Isoindoline compounds for use in the treatment of cancer | |
| EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
| TW200716546A (en) | Oxindole compounds and their uses as therapeutic agents | |
| EA201001365A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДУЕМОГО C-МЕТ ТИРОЗИНКИНАЗОЙ | |
| MX2010006739A (es) | Compuestos pirido[2,3-b]pirazina-8-sustituidos y su uso. | |
| NO2010002I2 (no) | Toceranibfosfat. | |
| RU2009138327A (ru) | Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака | |
| TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| EA200970953A1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
| WO2008063202A3 (en) | Heterobicyclic thiophene compounds for the treatment of cancer | |
| EA200870085A1 (ru) | Триазолопиридазины в качестве модуляторов тирозинкиназы | |
| MX2007004551A (es) | Compuestos tiadiazol y metodos de uso. | |
| BRPI0517921A (pt) | métodos para preparar compostos de indazol | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| RU2007110946A (ru) | Пиримидиновые производные | |
| EA200600921A1 (ru) | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний | |
| NO20061318L (no) | 6-[-(substituerte) fenyl] Triazolopyrimidiner somanticancer midler | |
| PE20050523A1 (es) | Pirazoles como inhidores de factor de necrosis tumoral | |
| RS20080497A (en) | Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof | |
| EA201592287A1 (ru) | Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения | |
| ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
| MX2011010732A (es) | Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer. | |
| DE60221283D1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |